Why would ACT issue a press release in variance from the actual paper published in Nature? To garner a mountain free, positive publicity, to be sure. But to what end? Follow the money. Here is a potential answer. In the wake of this mass media stampede, ACT’s stock has risen about 400%. Investors should do their due diligence more carefully. ACT has a history of money problems temporarily remedied by hyped stories about their supposed breakthroughs that later turn out to have been less than meets the eye.
